Medical Economics Logo
  • Physicians Money Digest

  • Physicians Financial News

  • Physicians Practice

  • Chief Healthcare Executive

  • Patient Care Online

All NewsCareersLegalMoneyOpinionPhysicians Financial NewsPractice ManagementTechnology
Around the PracticeBetween The LinesClinical ConsultExpert InterviewsMedical Economics PulseMedical World NewsOff The Charts PodcastsPhysician ReportPrimaryViewSlideshows
Academy
Conference CoverageConference Listing
Medical EconomicsPatient Care SupplementSponsored ContentSponsored ResourcesSupplements And Featured Publications
CME/CEJob BoardSubscribe
Financial Advisor Guide
CareersCareersCareersCareersCareersCareersCareersCareersCareers
LegalLegalLegalLegalLegal
Medical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & Technology
Opinion
Physician's Money DigestPhysician's Money DigestPhysician's Money DigestPhysician's Money Digest
PolicyPolicyPolicyPolicyPolicyPolicy
Practice FinancePractice FinancePractice FinancePractice FinancePractice FinancePractice FinancePractice Finance
Practice ManagementPractice ManagementPractice ManagementPractice ManagementPractice ManagementPractice ManagementPractice ManagementPractice Management
Practice TechnologyPractice TechnologyPractice TechnologyPractice TechnologyPractice TechnologyPractice TechnologyPractice Technology
Screening
Special ReportsSpecial ReportsSpecial Reports
Spotlight -
  • The benefits of a physician MBA program
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Physician Bootcamp
  • Physician Report
CareersCareersCareersCareersCareersCareersCareersCareersCareers
LegalLegalLegalLegalLegal
Medical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & Technology
Opinion
Physician's Money DigestPhysician's Money DigestPhysician's Money DigestPhysician's Money Digest
PolicyPolicyPolicyPolicyPolicyPolicy
Practice FinancePractice FinancePractice FinancePractice FinancePractice FinancePractice FinancePractice Finance
Practice ManagementPractice ManagementPractice ManagementPractice ManagementPractice ManagementPractice ManagementPractice ManagementPractice Management
Practice TechnologyPractice TechnologyPractice TechnologyPractice TechnologyPractice TechnologyPractice TechnologyPractice Technology
Screening
Special ReportsSpecial ReportsSpecial Reports
    • Academy
    • CME/CE
    • Job Board
    • Subscribe
Advertisement

Article

December 13, 2017

New shingles vaccine approved, recommended highly by ACIP

Author(s):

Rachael Zimlich, RN, BSN

There is a new vaccine against shingles, and ACIP has recommended that it replace its predecessor.

Clinicians now have a new way to fight shingles, and the vaccine has been listed as the preferred choice over its predecessor by at least one federal agency.
The U.S. Food and Drug Administration (FDA) approved Shingrix for adults aged 50 and older in October 2017, and Advisory Committee on Immunization Practices (ACIP) voted days later to recommend preferential use of Shingrix over Zostavax, which was the only shingles vaccine available until now. FDA's approval and ACIP's recommendation were based on a Phase III clinical trial program evaluating the vaccine's safety and efficacy in a cohort of more than 38,000 individuals. The trials showed 90% efficacy across all age groups, according to the vaccine's manufacturer GSK.

Shingles is caused by the reactivation of the varicella zoster virus (VZV), the same virus that causes chickenpox. Most adults have the virus in their system, but it lies dormant until reactivated--usually as an individual ages and their immune system declines. The reactivated virus presents with a painful, itchy rash that can last for weeks with pain continuing for months in more extreme cases. 

Len Friedland, MD, vice president of Scientific Affairs and Public Health at GSK, said there are more than 1 million new cases of shingles every year, and all adults have a 1 in 3 chance of developing the infection. In individuals aged 85 and older, that risk increases to 1 in 2, he said.

Len Friedland, MD

"Shingles can be really impactful and change people's lives," Friedland told Medical Economics. “Its clinical presentation is a very severe type of pain that can really stop people in their tracks. People refer to the pain as the type of pain they experience when they deliver a child or have a kidney stone.”

In addition to the pain of shingles infection, patients can experience acute complications including postherpetic neuralgia (PHN), a form of chronic nerve pain and the most common complication associated with shingles.

Zostavax was approved by the FDA in 2006 and has been the only vaccine for shingles until now. It is a live vaccine and licensed for patients 60 and older, according to the FDA.

Shingrix is a non-live vaccine using recombinant antigens and adjuvants to enhance immune response. Friedland said testing of the vaccine showed 90% efficacy in preventing the development of shingles over a four-year period.

“The results have proven that this approach has generated a high level of protection for people regardless of age,” Friedland said.

Next: Differences versus Zostavax

 

 

Differences vs. Zostavax

Friedland said Shingrix's approval for age 50 and older can offer protection to an additional 42 million at-risk patients. GSK is also investigating the use of Shingrix in immunocompromised patients over the age of 18--a group that cannot receive a live vaccine like Zostavax.

"It is well recognized that these patients are at a much higher risk of getting shingles and its complications," said Friedland. “There is tremendous interest in the development of a shingles vaccine for immunocompromised patients."

Friedland said additional data on the use of Shingrix in this population will be published as research is completed.

Aside from functionality, there are other differences between the two vaccines. Unlike Zostavax which is administered in one subcutaneous injection, Shingrix is administered over two intramuscular doses given two to six months apart. Patients must complete the full series for maximum protection, Friedland said.

“The reason it’s a two-dose vaccine is the early data clearly illustrated that giving two doses was going to give the type of strong immune response we were looking for to give this high level of protection," Friedland said. There also are storage and handling differences between the two vaccines. Zostavax must be frozen, and Shingrix is refrigerated, according to GSK. 
The most common side effects of Shingrix are pain, redness or muscle pain at the injection site, as well as fatigue, headache, shivering, fever and upset stomach.

Shingrix can be ordered now, but insurance coverage for the vaccine may be spotty at first. GSK expects payer coverage of the vaccine to become widespread by the first quarter of 2018. For patients opting to self-pay for the vaccine, the cost for the entire series is $280--$140 for the first shot and $140 for the second.

 

Newsletter

Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.

Subscribe Now!
Related Videos
Physician panelists discuss vaccine misinformation and policy in 2025
© Alliance for Aging Research
Related Content
Advertisement
physician stethoscope gavel: © megaflopp - stock.adobe.com
July 9th 2025

‘There is a lot of misinformation and disinformation out there’ about vaccines, says attorney in HHS lawsuit

Off the Chart: A Business of Medicine Podcast - Ep. 65: Patient autonomy with Jeffrey A. Singer, M.D.
May 19th 2025

Ep. 65: Patient autonomy with Jeffrey A. Singer, M.D.

covid-19 vial vaccine: © myskin - stock.adobe.com
July 7th 2025

‘Existential threat to vaccination’ — Physicians, public health experts sue HHS over RFK Jr’s COVID-19 vaccine directive

Off the Chart: A Business of Medicine Podcast - Physician panel: Navigating the 2025 vaccination crisis
May 7th 2025

Physician panel: Navigating the 2025 vaccination crisis

© ACIP
June 27th 2025

Thimerosal: Preservative or poison? ACIP debates mercury-based vaccine ingredient

ACIP votes on flu, RSV vaccines for upcoming 2025-2026 respiratory illness season
June 26th 2025

ACIP votes on flu, RSV vaccines for upcoming 2025-2026 respiratory illness season

Related Content
Advertisement
physician stethoscope gavel: © megaflopp - stock.adobe.com
July 9th 2025

‘There is a lot of misinformation and disinformation out there’ about vaccines, says attorney in HHS lawsuit

Off the Chart: A Business of Medicine Podcast - Ep. 65: Patient autonomy with Jeffrey A. Singer, M.D.
May 19th 2025

Ep. 65: Patient autonomy with Jeffrey A. Singer, M.D.

covid-19 vial vaccine: © myskin - stock.adobe.com
July 7th 2025

‘Existential threat to vaccination’ — Physicians, public health experts sue HHS over RFK Jr’s COVID-19 vaccine directive

Off the Chart: A Business of Medicine Podcast - Physician panel: Navigating the 2025 vaccination crisis
May 7th 2025

Physician panel: Navigating the 2025 vaccination crisis

© ACIP
June 27th 2025

Thimerosal: Preservative or poison? ACIP debates mercury-based vaccine ingredient

ACIP votes on flu, RSV vaccines for upcoming 2025-2026 respiratory illness season
June 26th 2025

ACIP votes on flu, RSV vaccines for upcoming 2025-2026 respiratory illness season

About
Advertise
Contact Us
Editorial Staff
Job Board
Terms and Conditions
Contributor Guidelines
Privacy Policy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.